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Abstract
Background: To investigate the role of maspin expression in the progression of gastrointestinal stromal tumors,
and its value as a prognostic indicator.
Methods: In the study 54 patients with GIST diagnosis were included in Uludag University of Faculty of Medicine,
Department of Pathology between 1997-2007. The expression of maspin in 54 cases of gastrointestinal stromal
tumor was detected by immunohistochemistry and compared with the clinicopathologic tumor parameters.
Results: The positive expression rates for maspin in the GISTs were 66,6% (36 of 54 cases). Maspin overexpression
was detected in 9 of 29 high risk tumors (31%) and was significantly higher in very low/low (78.6%) and
intermediate-risk tumors (63.6%) than high-risk tumors.
Conclusions: Maspin expression might be an important factor in tumor progression and patient prognosis in GIST.
In the future, larger series may be studied to examine the prognostic significance of maspin in GISTs and, of
course, maspin expression may be studied in different mesenchymal tumors.
Background
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal
tract. These tumors may occur in any region but are
most commonly reported in the stomach and the small
intestine [1-7]. GISTs originate from the neoplastic
transformation of the intestinal pacemaker cell, the
interstitial cell of Cajal. Cajal cells are neuron-derived
cells that migrate from the neural crest to the intestine,
and the GISTs stemming from these are different from
classical mesenchymal tumors such as leiomyoma [8].
GISTs have a wide spectrum of biological behavior
ranging from benign to malignant [1,2]. Despite clearly
defined conventional histological criteria such as tumor
size and mitotic index, the prediction of the clinical
course of these tumors is often difficult [6]. Therefore it
is important to investigate alternative markers that allow
better prognostic assessment.
Maspin (mammary serine protease inhibitor) is a
member of the serpin superfamily of protease inhibitors,
which also acts as a tumor suppressor [9]. The mechan-
ism of its tumor suppressor effect is still not understood
clearly. It is suggested that maspin prevents invasion
and metastases of tumors by inhibiting tumor-induced
angiogenesis and tumor cell motility [10-13]. In addi-
tion, it is reported to induce apoptosis of neoplastic
cells [14]. Maspin expression has been demonstrated in
multiple tissues including breasts, prostate, placenta,
small intestine, colon, uterus, kidney, thymus, and testis
[15-18]. On the other hand, it is expressed at different
levels in many solid tumors. In breast, colon, stomach,
thyroid, bladder, and prostate cancers, in lung and oral
cavity squamous cell carcinoma, and in certain renal
neoplasms, maspin expression seems to predict a better
prognosis [13,19-22]. In contrast, some studies have
shown that maspin overexpression is correlated with a
poor prognosis in pancreatic and ovarian cancers and in
lung adenocarcinoma [23-25].
To the best of our knowledge, no study yet exists
about the presence of maspin expression in mesenchy-
mal and neural tumors. On the other hand, existing stu-
dies report that maspin expression does not occur in
mesenchymal tissue other than corneal stromal cells.
Similarly, GISTs have not yet been studied in relation to
maspin expression and prognostic meaning. The aim of
this study was an immunohistochemical evaluation of
maspin expression in these tumors.
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Between 1997 and 2007, fifty-four patients with GIST
who underwent surgical resection in Uludag University
of Faculty of Medicine were selected for this study.
Seven of the patients had distant metastasis at the time
of presentation. Ethical approval was obtained for
the study. All specimens of the 54 patients showed posi-
tive CD117 and/or CD34 immunostaining. According to
the classification system proposed by Fletcher et al.
(Table 1), 29 (53.7%) patients belonged to the high-risk
group. Forty-two (77.8%) patients had tumors ≥ 5c m ,
a n d3 2( 5 9 . 2 % )h a dm i t o t i cc o u n t s≥ 5/50 high power
fields (HPF).
Immunohistochemistry
The cellular expression of maspin was assessed by immu-
nohistochemistry (IHC) using specific antibody on
routinely processed blocks of formalin-fixed and paraffin-
embedded surgical specimens of the tumors. The 4 μm
sections of tumor tissues were mounted on poly-L-lysine
coated slides. The sections were deparaffinized in xylene
(25 min) and rehydrated through serial baths of alcohol
to water. Antigen retrieval was applied with pressure
cooking using 500 ml 1 mM diluated EDTA-Saline buffer
(pH = 8). After using H2O2 treatment for 15 minutes to
remove endogenous peroxidase activity, nonspecific
blockage with ultrablock nonspecific blocking agent (Lab-
vision Co.) was performed on all sections for 10 minutes.
Then the sections were incubated with primary antibody
maspin AB-1 (Clone EAW24, Mouse monoclonal anti-
body, Thermo Scientific, USA) 1/20 in dilution at room
temperature for 30 minutes. The antibody-treated slides
were rinsed in phosphate-buffered saline solution and
incubated with a biotinylated secondary antibody (Ultra-
vision-Labcision Co., Fremont, CA, U.S.A.). The slides
were washed in phosphate-buffered saline and then incu-
bated with an avidin-biotin-preoxidase complex (Ultra-
streptavidin/HRP, Labvision Co.) for 30 minutes. As a
chromogen, 3-3’-diamino-benzene tetrahydrochloride was
used with hydrogen peroxide. The slides were finally
counterstained with hematoxylin. Prostate tissue was
used as positive control.
Evaluation of staining for Maspin
Maspin expression was determined semiquantitatively by
the percentage of stained cells, the staining intensity,
and subcellular localization [23].
￿ The percentage of positive cells was rated as follows:
0 points, no positive cells; 1 point, 0-5%; 2 points,
6-50%; 3 points, 50-100% positive cells.
￿ Staining intensity was rated as follows: 1 point,
weak intensity; 2 points, moderate intensity; 3 points,
strong intensity.
￿ Points for intensity and the percentage of positive
cells were added to obtain an overall maspin score
(OMS) [0-3]. Lesions were categorized into four
groups:
1) Negative (OMS = 0): < 5% stained cells
regardless of intensity
2) Weak expression (OMS = 1): 3 points
3) Moderate expression (OMS = 2): 4-5 points
4) Strong expression (OMS = 3): 6 points
￿ OMS 2 & 3 was considered as overexpression.
Statistical analysis
All statistical analyses were performed using SPSS (Sta-
tistical Package for the Social Sciences, Chicago, IL) for
Windows version 15.0. Survival time was calculated
starting from the date of initial surgery.
The Chi-square and Fisher’se x a c tt e s t sw e r eu s e dt o
evaluate correlations between variables. P <0 . 0 5w a s
considered statistically significant. Survival times were
calculated by using the Kaplan-Meier method and com-
pared with the log-rank test.
Results
Of the 54 patients included in this study, 35 (64.8%)
were male and 19 (35.2%) were female (Table 2). The
mean age was 55.8 years (range 17-75 years). Tumor
localizations were as follows: 23 stomach (42.6%), 18
small intestine (33.3%), 10 mesentery (18.5%), 2 large
intestine (3.7%), and 1 esophagus (1.85%). The sizes of
tumor varied between 2 and 29 cm (median 7 cm).
Mitotic count varied between 0 and 61 mitoses per 50
HPF (median 11).
Among 54 tumors, 18 were OMS = 0; 9 were OMS =
1; 8 were OMS = 2; and 19 were OMS = 3 (Figure 1).
When risk groups were compared, a meaningful differ-
ence was observed between low- and high-risk groups,
as well as between intermediate- and high-risk groups
(chi square test: P = 0,009; P = 0,029)(Table 3).
Follow-up period ranged between 2 and 115 months
(median: 40.77 months). At the end of the follow up, 37
patients were alive without any evidence of the disease,
while 16 had died of the disease and one patient with
Table 1 Risk of Aggressive Behavior in GISTs (Fletcher et
al, 2002)
Size (largest dimension) Mitotic Count
Very low risk <2 cm < 5/50 HPF
Low risk 2-5 cm < 5/50 HPF
Intermediate risk <5 cm 6-10/50 HPF
5-10 cm < 5/50 HPF
High risk >5 cm > 5/50 HPF
>10 cm any mitotic rate
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of diagnosis, metastasis was seen in 7 of the high risk
tumor patients, and not in others. Overexpression was
o b s e r v e di no n l y1o ft h e s e7p a t i e n t s .T h em a s p i n+ / -
ratio in the 47 non metastatic patients was 21/26 (p =
0,050).
Overall mean survival length was 54.67 months. It was
56.19 months in maspin (+) patients and 53.29 months
in maspin (-) patients. There was no difference in survi-
val rates between the groups (p > 0.05).
Discussion
GISTs are a rare special mesenchymal tumor group,
making up less than 1% of primary tumors of the gas-
trointestinal system [1]. Their biological behavior is hard
to predict [2]. Many macroscopic and microscopic para-
metres have been suggested to identify the prognosis,
including tumor localization and diameter, invasion of
peripheral tissue, growth pattern, mucosal invasion, pre-
dominant tumor cell type, cellularity, nuclear pleo-
morphism, mitotic count, Ki67 proliferative activity
index, p53 gene mutation, histological grade, DNA ana-
lysis, margins of surgical operation, necrosis and immu-
nophenotyping [1-7]. Even though efforts continue for
Table 2 Clinicopathological characteristics of GIST
patients
Variable n
Age, yr 55,83 ± 12,93
Gender (Male/Female) 35/19
Tumor size
5c m< 1 2
5c m≥ 42
Mitosis (50 HPP)
5< 2 2
5 ≥ 32
Localization
Stomach 23
Small intestine 18
Large intestine 2
Meso-peritoneum 10
Eusophagus 1
Risk Group
Low (very low and low) 14
Intermediate 11
High 29
Figure 1 A) OMS score (-), B) OMS score (1+), C) OMS score (2+), D) OMS score (3+) staining paterns in GIST’s.
Table 3 Correlation of clinicopathological variables with
maspin overexpression.
Maspin overexpression
Variable 54 (%) No (n = 27)
(% 50)
Yes (n = 27)
(% 50)
P value
Size 0,769
5c m< 1 2 6 6
5c m≥ 42 21 21
Mitotic count (50 BB) 0,525
5 < 22 7 15
5 ≥ 32 20 12
Risk Group (compared with high risk group and others)
Very low and low 14 3 11 0,009
Intermediate 11 4 7 0,029
High 29 20 9
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and mitotic index (mitotic count/50 BBA) currently
remain the most important morphological criteria for
the prediction of tumor behavior [2,6].
Proteinases and proteinase inhibitors are known to
play an important role in tumor invasion and metastasis.
Proteinases degrade the extracellular matrix, while their
inhibitors antagonize this process. Two classes of protei-
nases have been extensively studied: serine proteinases
and their inhibitors, and metalloproteinases and their
inhibitors [26]. Maspin (mammary serine protease inhi-
bitor) is structurally a member of the serpine (serine
protease inhibitors) superfamily [27]. Studies have
revealed that maspin is largely an intracellular protein,
which is soluble in the cytoplasm and associated with
secretory vesicles. It is located at the cell membrane
interface with extracellular matrix and does not act as a
classical inhibitory serpine with antiprotease activity
against trypsin-like proteases [28].
Maspin expression has been shown in the literature in
epithelial and myoepithelial cells in certain tissues, most
notably in the breasts and prostate, as well as neoplasms
stemming from these tissues [15-18]. Many articles have
described a negative association between maspin expres-
sion and carcinoma progression in several malignancies,
including those of the breast, prostate, colon, bladder,
thyroid and stomach cancers, lung and oral cavity squa-
mous cell carcinoma, and some renal neoplasms
[13,19-22]. Chen and Yates reported that maspin has
suppressive effects on invasion and metastasis of
carcinoma [29]. However, enhanced maspin expression
may have an impact on different steps in the progres-
sion to pancreatic and ovarian carcinoma [23-25]. In
addition, different results were also obtained for the
same cancer type in different studies [21,30]. These con-
tradictory results might result from specific regulation
in different organs or the different genetic backgrounds
of the populations studied, although definite evidence
for a paradoxical mechanism remains elusive.
While existing studies reportt h a tm a s p i ne x p r e s s i o n
does not occur in mesenchymal and neural crest cells
other than corneal stromal cells, the literature does not
include any studies about maspin expression in
mesenchymal and neural tumors, except gliomas
[18,31,32]. Similarly, no study exists to show the rela-
tionship between maspin expression and prognosis in
GIST patients.
Although the molecular and biological mechanisms of
the function(s) of maspin remain largely unknown at
present, there is evidence that maspin interacts with the
p53 tumor suppressor pathway and may function as
inhibitor to cell motility, invasion, metastasis and angio-
g e n e s i si nv i t r oa n di nv i v o[ 2 3 ] .A l s o ,m a s p i na p p e a r s
to be regulated by wild-type p53. Zou et al. reported
that there was robust induction of maspin in prostate
and breast cancer cells after wild-type p53 expression
[33]. p53 was found to activate maspin promoter by
binding directly to the p53 consensus binding site pre-
sent in the maspin promoter. Some GISTs are known to
harbor p53 gene mutations [34,35].
Figure 2 Positive staining in tumor cell’s cytoplasm for maspin (short arrow) but not stain in endothelial cells (long arrow). (×200)
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maspin expression in GIST cases. We immunohisto-
chemically observed maspin staining in 36 (66,6%) out
of our 54 cases. In half of these patients, we obtained
5% or more positive cytoplasmic staining with maspin,
whereas in 16,6% of them we obtained less than 5%
staining. In the blocks we studied, we detected cytoplas-
mic staining with maspin in the mucosa epithelium of
normal tissues belonging to the gastrointestinal tract
neighboring the tumor, but no staining in mesenchymal
cells (smooth muscle cells, endothelial cells, etc.). No
staining occurred in the endothelial cells of tumor tissue
either (Figure 2). Following these, we analyzed the prog-
nostic significance of maspin expression in GISTs.
In our study, maspin expression was significantly corre-
lated with the risk grade of GISTs. Maspin overexpres-
sion was detected in 9 of 29 high risk tumors (31%) and
was significantly higher in very low/low- (78.6%) and
intermediate-risk tumors (63.6%) than high-risk tumors.
As low-risk patients have higher maspin overexpression
and high-risk patients have less, it may be claimed that
maspin overexpression is a favorable prognosis marker.
Conclusions
Our preliminary results suggest that expression level of
maspin may be considered a predictor of prognosis in
GISTs. Future studies with larger patient numbers will
be essential to confirm the pr o g n o s t i cs i g n i f i c a n c eo f
maspin in patients with GIST and other mesenchymal
tumors.
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